Literature DB >> 3903335

[Local treatment of corneal transplants in the human with cyclosporin A].

F Hoffmann, M Wiederholt.   

Abstract

Cyclosporin eye drops (2% in miglyol) were administered in 4 glaucoma patients for postoperative treatment following keratoplasty. In the course of the 2-year follow-up period, one patient evidenced an immunoreaction that led to clouding of the transplant. In 25 patients, Cyclosporin eye drops (2% in castor oil) were given in combination with low-dose dexamethasone eye drops (0.1%). During a mean follow-up period of 10 months (5 to 14 months), 4 transplants clouded as the result of an immunoreaction. The intraocular pressure was not influenced by the combination therapy in 21 patients who did not have a history of glaucoma but increased slightly in 3 of 4 patients who did. Since Cyclosporin A had no influence on the stromal wound healing, it was possible to remove the corneal sutures 5 months postoperatively. All patients developed keratopathia punctata and slight conjunctivitis. The epithelial defects, which often showed a vortex-like pattern, appeared at the end of the first postoperative week and were usually no longer detectable after 4 months. The tear production (Schirmer test) was not influenced or only slightly increased by Cyclosporin. Corneal infiltrates did not occur. If one compares the effects and side effects of Cyclosporin and dexamethasone, local application of Cyclosporin in combination with low-dose dexamethasone appears to be an effective treatment for corneal transplantation in Man.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3903335     DOI: 10.1055/s-2008-1050995

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  7 in total

Review 1.  Immunology of corneal transplantation.

Authors:  W H Constad; K Taraschanskiy
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

2.  Systemic cyclosporin A in high failure risk, repeated corneal transplantation.

Authors:  S Rumelt; V Bersudsky; T Blum-Hareuveni; U Rehany
Journal:  Br J Ophthalmol       Date:  2002-09       Impact factor: 4.638

3.  Topical treatment of severe corneal ulcers with cyclosporin A.

Authors:  M Zierhut; H J Thiel; E G Weidle; R Waetjen; U Pleyer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

Review 4.  Systemic cyclosporine and corneal transplantation.

Authors:  Mohammed Ziaei; Fatemeh Ziaei; Bita Manzouri
Journal:  Int Ophthalmol       Date:  2016-02       Impact factor: 2.031

Review 5.  Topical ciclosporin in the treatment of ocular surface disorders.

Authors:  S Tatlipinar; E K Akpek
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

6.  Systemic cyclosporin A in high risk penetrating keratoplasties: a case-control study.

Authors:  A C Poon; J E Forbes; J K Dart; S Subramaniam; C Bunce; P Madison; L A Ficker; S J Tuft; D S Gartry; R J Buckley
Journal:  Br J Ophthalmol       Date:  2001-12       Impact factor: 4.638

7.  Influence of topical cyclosporine A and dissolvent on corneal epithelium permeability of fluorescein.

Authors:  J M Benítez del Castillo; A Castillo; N Toledano; S Durán; C del Aguila; M Otero; J García-Sanchez
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.